glp-1 agonist fda approval Would love to know what you think about this and where you agree and where you disagree? These are next-generation incretin therapies that are in late-stage clinical development and have the potential The New Weight Management Meds

Pei L., Shen X., Yan Y., et al., Virtual Screening of the MultiPathway and MultiGene Regulatory Molecular Mechanism of Dachengqi Decoction in the Treatment of Stroke Based on Network Pharmacology, Combinatorial Chemistry & High Throughput Screening 23, no

Conclusions and Relevance GLP-1 RA therapy in IIH is associated with significant reductions in medication use, symptoms/signs, and procedural interventions, suggesting its potential as a management strategy

Your body can feel the effects of a boosted metabolism as your energy increases, contributing to an increased rate of calorie burning daily

Retatrutide is more accurately described as an investigational triple-receptor medication targeting GLP-1, GIP, and glucagon pathways

The models have been used to predict pharmacokinetics in special populations, including those with hepatic or renal impairment, as well as in disease states such as type 2 diabetes and obesity

Details of the National Institutes of Health-funded study were published this week in a Nature paper titled A brain reward circuit inhibited by next-generation weight-loss drugs in mice. In it, the team reported that they investigated the small-molecule GLP-1s including Eli Lillys recently approved drug orforglipron, also known by the brand name Foundayo, as well as danuglipron, an oral GLP-1 that was being developed by Pfizer until the company decided to discontinue its development in 2025